Oramed Pharmaceuticals Inc.

Special purpose acquisition corporations did not have a very successful run in the last SPAC wave to hit the life science sector, but a new round of the vehicles that provide companies an alternative

Mineralys Therapeutics, Inc. , which launched the largest biopharmaceutical company initial public offering so far this year late on 9 February, was an ideal IPO candidate under current market conditi

Oramed Pharmaceuticals Inc. has joined the list of companies that have fallen short in the development of an oral formulation of insulin and the failure of ORMD-0801 in a late-stage diabetes trial ha

Akero Therapeutics, Inc. ’s successful Phase IIb data with efruxifermin (EFX) in pre-cirrhotic non-alcoholic steatohepatitis (NASH) patients provided good news for the company, but also more generally